Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Milestone Pharmaceuticals Inc (MIST)

Milestone Pharmaceuticals Inc (MIST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 146,491
  • Shares Outstanding, K 85,169
  • Annual Sales, $ 0 K
  • Annual Income, $ -41,520 K
  • EBIT $ -57 M
  • EBITDA $ -57 M
  • 60-Month Beta 0.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.55

Options Overview Details

View History
  • Implied Volatility 180.36% (+20.81%)
  • Historical Volatility 51.64%
  • IV Percentile 43%
  • IV Rank 18.06%
  • IV High 645.74% on 04/03/25
  • IV Low 77.80% on 01/21/26
  • Expected Move (DTE 7) 0.5610 (33.10%)
  • Put/Call Vol Ratio 4.89
  • Today's Volume 53
  • Volume Avg (30-Day) 1,214
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 58,181
  • Open Int (30-Day) 55,343
  • Expected Range 1.1340 to 2.2560

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 3
  • High Estimate -0.16
  • Low Estimate -0.21
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6800 +0.30%
on 02/13/26
2.1300 -20.89%
on 01/15/26
-0.2450 (-12.69%)
since 01/13/26
3-Month
1.6100 +4.66%
on 12/12/25
3.0600 -44.93%
on 12/12/25
-0.2150 (-11.32%)
since 11/13/25
52-Week
0.6300 +167.46%
on 04/09/25
3.0600 -44.93%
on 12/12/25
-0.6050 (-26.42%)
since 02/13/25

Most Recent Stories

More News
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance...

MIST : 1.7000 (-1.16%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...

MIST : 1.7000 (-1.16%)
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially insured...

MIST : 1.7000 (-1.16%)
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

 European decision on approval is expected by Q1 2027 If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the...

MIST : 1.7000 (-1.16%)
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

Novel treatment for PSVT developed with Milestone Pharmaceuticals

MIST : 1.7000 (-1.16%)
ATR : 142.12 (+1.15%)
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT  Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT...

MIST : 1.7000 (-1.16%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...

MIST : 1.7000 (-1.16%)
Milestone Pharmaceuticals: Q3 Earnings Snapshot

Milestone Pharmaceuticals: Q3 Earnings Snapshot

MIST : 1.7000 (-1.16%)
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential...

MIST : 1.7000 (-1.16%)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...

MIST : 1.7000 (-1.16%)

Business Summary

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 1.9467
2nd Resistance Point 1.8933
1st Resistance Point 1.8067
Last Price 1.7000
1st Support Level 1.6667
2nd Support Level 1.6133
3rd Support Level 1.5267

See More

52-Week High 3.0600
Fibonacci 61.8% 2.1317
Fibonacci 50% 1.8450
Last Price 1.7000
Fibonacci 38.2% 1.5583
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar